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Nanoscale Self-Assembled Multivalent (SAMul) 
Heparin Binders in Highly Competitive, 
Biologically Relevant, Aqueous Media 
Stephen M. Bromfield,a,ȟ Paola Posocco,b,c,ȟ Ching Wan Chan,a Marcelo 
Calderon,d Scott R. Guimond,e Jeremy E. Turnbull,e Sabrina Pricl,b,c,* and 
David K. Smith*a 
This paper investigates small molecules that self-assemble to display multivalent ligand arrays 
for heparin binding.  In water, the self-assembled multivalent (SAMul) heparin binder is highly 
competitive with the current clinical heparin reversal agent, protamine.  On addition of salt, the 
dimensions of the self-assembled nanostructure increase.  This unique feature is due to the 
dynamic, responsive nature of assembly, predicted using multiscale modelling and proven 
experimentally, enhancing heparin binding of SAMul systems relative to fixed covalent 
multivalent nanostructures.  Conversely, the presence of serum adversely affects the heparin 
binding of SAMul systems relative to covalent nanostructures due to partial destabilisation of the 
assemblies.  Nonetheless, clotting assays in human plasma demonstrate that the SAMul system 
acts as a functional heparin reversal agent.  Compound degradation, inducing nanostructure 
disassembly and loss of SAMul binding, takes place over 24 hours due to ester hydrolysis ± but 
when bound to heparin, stability is enhanced.  Heparin reversal in plasma, and the 
therapeutically useful degradation profile, make this SAMul approach of potential therapeutic 
value in replacing protamine, which has a number of adverse effects when used in the clinic . 
 
Introduction  
There is intense activity in the emerging field of 
nanomedicine.1  Biomolecules and biological structures have 
nanoscale dimensions, and designing synthetic systems which 
can interact with biological targets on the nanoscale is therefore 
an area of key interest.2  Multivalency is an effective and 
widely employed way of achieving high-affinity interactions 
between nanoscale surfaces.3  However, covalent multivalent 
systems often involve complex multi-step syntheses, and may 
persist in vivo long after they have had their desired effect.  
One approach to making multivalent systems which are 
synthetically simpler and more responsive is to design low-
molecular-weight drug-like ligands, which spontaneously self-
assemble into a nanoscale ligand array ± Self Assembled 
Multivalency (SAMul).4  This approach has been used to 
organise a range of ligands, including saccharides and peptides, 
and enhance their binding to nanoscale biological surfaces.5 
 A particularly interesting nanoscale target for binding is 
heparin (Fig. 1).6  This anionic polysaccharide plays key roles 
in the coagulation cascade, and is in widespread clinical use as 
an anti-coagulant during surgery.7  In the clinic, after surgery, 
the effect of heparin must be reversed so clotting can begin.  
This is typically achieved using protamine (Fig. 1), a cationic 
arginine-rich protein which binds heparin electrostatically.8  
Unfortunately, protamine causes adverse effects in a significant 
number of patients,9 which limits its ability to be applied at 
high doses.  This can lead to problems with heparin rebound.10 
Figure 1.  Major heparin disaccharide repeat unit (left) and a typical protamine 
(right, box). 
 A number of approaches have been taken to develop 
heparin binders as possible synthetic protamine replacements.6  
Most of these make use of cationic compounds which bind 
heparin electrostatically.11  To achieve high affinity binding, 
multivalent cationic polymers and dendrimers have been used.12  
In general, however, such systems are either well-defined but 
expensive, or lower-cost but poorly-defined.  Furthermore, 
cationic polymers often have poor toxicity profiles.13  The 
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limitations of previous approaches to protamine replacement 
therapy encouraged us to explore an innovative self-assembly 
approach to multivalent heparin binding.  Self-assembly can 
rapidly yield nanoscale multivalent surfaces for heparin binding 
± these structures should be more responsive than traditional 
covalent systems.  We recently reported that ligand C22-G1 
(Fig. 2) assembled into micellar nanostructures with a critical 
micelle concentration (CMC) of 4 PM in phosphate buffered 
saline at pH 7.5, and bound heparin.14  However, these studies 
were only performed in pure water ± we wanted to understand 
these nanostructures in more challenging and bio-relevant 
conditions, and the influence of this on SAMul binding.  This 
new paper reports the results, clearly demonstrates the unique 
advantages and limitations of a SAMul approach, and reports 
functional heparin reversal in human plasma. 
Figure 2.  Heparin binder C22-G1. 
Results and Discussion 
Effect of Biological Salt Levels on SAMul Heparin Binding 
The assay we previously employed to monitor solution-phase 
heparin binding with C22-G1 used methylene blue (MB, Fig. 
3) as a competitive dye, and only worked at very low ionic 
strengths (ϐ5 mM NaCl) and buffer concentrations (1 mM Tris 
HCl).14  In the absence of salt, C22-G1 required 86% as much 
charge as protamine to displace half of the MB from its 
complex with heparin.  We reasoned that our recent report of 
the new Mallard Blue (MalB) dye,15 would allow us to develop 
an assay for much more highly competitive conditions.  Indeed, 
we recently exemplified a new competition assay using MalB, 
in which PAMAM dendrimers displaced the dye from its 
heparin complex and the UV-Vis spectroscopic response 
quantified their relative binding abilities.16  We therefore 
performed this competition assay at biologically relevant salt 
and buffer conditions (150 mM NaCl and 10 mM Tris HCl). 
 Data are reported in terms of the effective concentration 
required to displace half of the MalB (EC50) from heparin, the 
charge excess of cationic binder at this point (CE50, i.e., the 
cation/anion ratio, assuming that C22-G1 is tetra-cationic, and 
the disaccharide repeat unit of heparin is tetra-anionic with an 
average Mr of 665.4) and the effective dose of the binder (given 
in mg per 100 international units [IU] of heparin).  As supplied, 
heparin only contains ~30-40% of chains with the sequence of 
pentasaccharide repeat units conferring high anti-coagulant 
activity.  However, all of the material contains anionic 
saccharides, even if not active, which will be bound by cationic 
systems.  The heparin concentration in the assay (27 PM, 
assuming average Mr of 665.4) refers to the total concentration 
of anionic disaccharide, irrespective of whether it is in the 
active form or not, and this value is used to calculate the CE50, 
value.  However, for calculatinJ WKH µGRVH¶ ZH UHIHUHQce the 
activity of the heparin binder only to the clinically active 
portion of heparin (as given in international units). 
Figure 3.  Methylene Blue (MB) and Mallard Blue (MalB) dyes used in 
competition assays to monitor heparin binding. 
7DEOH+HSDULQ%LQGLQJ'DWDIURP0DO%&RPSHWLWLRQ$VVD\VXVLQJȝ0
0DO%DQGȝ0KHSDULQLQP07ULV-HCl and 150 mM NaCl. 
Binder EC50 (PM) CE50 Dose 
(mg/100IU) 
C22-G1 7.50 ± 1.22 0.28 ± 0.05 0.23 ± 0.04 
Protamine 2.34 ± 0.23 0.52 ± 0.05 0.32 ± 0.03 
G2-PAMAM 2.55 ± 0.32 0.38 ± 0.04 0.25 ± 0.03 
G4-PAMAM 0.64 ± 0.04 0.38 ± 0.02 0.27 ± 0.02 
 
 Table 1 indicates that under these highly competitive 
conditions, protamine and C22-G1 bind effectively to heparin 
and readily displace MalB.  The concentration of C22-G1 
required to displace half of MalB (EC50) is significantly greater 
than that of protamine (or the PAMAM dendrimers), but this 
simply reflects the fact that C22-G1 is a low-molecular-weight 
drug-like system with only 4 positive charges, while protamine 
has 24.  Interestingly, the EC50 value of 7.5 PM is above the 
critical aggregation concentration of 4 PM calculated by Nile 
Red Assay17 ± indicative that self-assembly is required for 
effective multivalent binding. 
 A fairer comparison between heparin binders is provided by 
their charge efficiencies (CE50).  Here, C22-G1 significantly 
outperforms protamine (indeed C22-G1 only requires ca. 54% 
as much charge as protamine to displace MalB). This MalB 
assay therefore suggests that in high, biologically relevant 
amounts of salt, C22-G1 significantly improves its heparin 
binding performance relative to protamine ± in the absence of 
salt, C22-G1 needed 86% as much charge as protamine.  
Furthermore, C22-G1 was active in this assay at a very low 
dose (better than any of the covalent nanostructures). 
 It is worth noting that 7.5 PM C22-G1 displaces half the 
MalB from heparin ([MalB] = 25 PM).  As such, C22-G1 is a 
significantly better heparin binder than MalB, which is itself 
already highly optimised for heparin binding in terms of shape 
and charge organisation.15  This strongly suggests that self-
assembly is indeed assisting multivalent binding of C22-G1.  
Interestingly, C22-G1 even outperforms the best PAMAM 
dendrimers on a per charge and dose basis, in spite of the fact 
that G2-PAMAM has 16 positive surface charges and G4-
PAMAM has 64.  This clearly indicates C22-G1 is using more 
than just four charges on an individual molecule to bind 
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heparin, and that self-assembly is marshalling positive charges 
to achieve high affinity binding ± self-assembled multivalency 
(SAMul).  In the absence of hydrophobic modification, such 
compounds are incapable of binding heparin ± in agreement 
with our previous observations of SAMul DNA binding.18 
 Further evidence that self-assembly plays an important role 
in heparin binding is provided by scanning electron microscopy 
(SEM).  As previously reported,14 on drying mixtures of C22-
G1 and heparin, nanoscale micelles were observed clustered on 
the heparin surface (Fig. 4), clearly demonstrating that the 
nanostructures remain intact and do not appear to significantly 
disassemble or rearrange in the presence of heparin.   
Figure 4.  Scanning electron microscopy (SEM) image of C22-G1 nanostructures 
in the presence of heparin, dried from aqueous solution.  Reproduced with kind 
permission from Wiley-VCH.
14 
 In our new work, this observation was also supported in the 
solution phase by carrying out the Nile Red assay on C22-G1 
in the presence of heparin.  Nile Red was still solubilised, 
demonstrating that self-assemblies with a hydrophobic domain 
were still being formed in the presence of heparin. The critical 
aggregation concentration (CAC) increased slightly to 14 PM, 
which may suggest some destabilisation, but clearly C22-G1 is 
still able to self-assemble in the presence of heparin. 
The comparison of C22-G1 with protamine and PAMAM 
dendrimers suggests that the flexible, responsive nature of the 
self-assembled array may allow C22-G1 to better interact with 
heparin than the covalently fixed polycations.  To probe this 
further, and to discover why salt improves the relative heparin 
binding ability of C22-G1, we turned to multiscale molecular 
modelling.19  Using a combination of molecular dynamics (MD) 
and mesoscale modelling (dissipative particle dynamics, DPD), 
we gained unique insight into the self-assembly of this type of 
object in different media across multiple length scales. In this 
multiscale approach, we initially refine the structure of C22-G1 
by MD methods.  We then parameterise and coarse-grain the 
structure, which allows us to use DPD methods to refine the 
structure of self-assemblies of multiple C22-G1 molecules.  We 
then overlay MD information onto the coarse-grained 
mesoscale assemblies and gain further detailed information into 
the energetics of assembly and binding.  All of this modelling is 
performed in an appropriate solvent medium. 
 The simulations suggested that the addition of salt 
significantly changed the dimensions of the self-assembled 
nanostructures formed by C22-G1, which become much larger 
in 150 mM NaCl (Fig. 5).  It is known that micellar aggregates 
can enlarge in response to increasing ionic strength,20 an effect 
normally explained in terms of salt-mediated screening of 
micellar surface charge and an increasing contribution of the 
hydrophobic effect.  These effects allow a larger number of 
individual surfactant molecules to be incorporated into the self-
assembled nanostructures, hence enlarging them. 
Figure 5.  Mesoscale (top panel) and atomistic (bottom panel) models of self-
assembled C22-G1 under 150 mM NaCl (left) and no salt (right) conditions. In the 
upper panel, the hydrophobic portion of the C22-G1 molecules is shown as teal 
sticks while the hydrophilic corona is portrayed in plum. The solvent and ions 
molecules are visualized as a continuum grey field. In the lower panel, the C22-
G1 molecules appear as steel blue sticks-and-balls. Some representative water 
molecules, Na
+
 and Cl
-
 ions are also shown as light blue, orange, and grey CPK 
spheres, respectively. 
 Specifically, our simulations predict that at physiological 
ionic strength, C22-G1 self-assembles into well-defined 
spherical micelles with an aggregation number (Nagg) of 24 ± 1, 
a total charge (Qtot) of 96 ± 4, and an average micellar diameter 
(Dm) of 9.3 ± 0.1 nm. The absence of salt again results in the 
formation of spherical assemblies; but with a much smaller Nagg 
(11 ± 3) and Qtot (44 ± 12) and, consequently, smaller 
dimensions (Dm = 6.3 ± 0.5).  This change in dimensions results 
from a combination of charge screening and increased 
hydrophobic effect which, in turn, reflect in a variation of the 
corresponding values of the mesoscale interaction parameters 
(see Table S1).  This result suggests that the non-covalent 
nature of the SAMul nanostructure allows it to respond to the 
environment in which it finds itself, and hence modify its size.  
Clearly a covalently bound nanostructure would be unable to do 
this to the same extent. 
 To confirm the predicted change in dimensions 
experimentally, we carried out dynamic light scattering (DLS) 
in the absence and presence of salt (Table 2). In the presence of 
150 mM NaCl, the self-assembled nanostructure is indeed 
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significantly larger than in the absence of electrolyte.  As such, 
the experimental study is fully supportive of the proposals 
forthcoming from multiscale modelling. 
Table 2.  Micellar aggregate diameter of C22-G1 in the absence and presence 
of 150 mM NaCl as measured by DLS. 
Media Diameter 
(nm) 
Peak Width 
(nm) 
10 mM Tris HCl 5.8 ± 0.5 2.0 
10 mM Tris HCl, 150 mM NaCl 9.1 ± 0.1 2.1 
 
Figure 6.  Atomistic models of self-assembled C22-G1 (top panel), Protamine 
(middle panel), and G2-PAMAM (bottom panel) under no salt (left) and 150 mM 
NaCl (right) conditions. C22-G1 is shown as teal sticks, protamine as a light blue 
ribbon with residues highlighted as sticks, and G2-PAMAM as dark slate sticks. 
Heparin is in dark olive green (L-iduronic acid) and light green (D-glucosamine) 
spheres. Water molecules are omitted for clarity while some Na
+
 and Cl
-
 ions are 
shown as orange and grey spheres, respectively. 
 Given the diameter of the SAMul nanostructures increases 
on the addition of salt, we reasoned this may provide a 
mechanism through which these self-assembled structures 
improve their heparin binding relative to protamine as ionic 
strength increases.  We used multiscale modelling to compare 
the thermodynamics of interaction of the different micellar 
structures, protamine and G2-PAMAM with heparin (Table 3, 
Fig. 6). 
 In the presence of salt, C22-G1 binds heparin more 
effectively (ȟ
ୠ୧୬ୢୣ୤୤ ൌ  െ ? ?Ǥ ?Ȁሻ  than in its absence 
(ȟ
ୠ୧୬ୢୣ୤୤ ൌ  െ ? ?Ǥ ?ȀሻǤ  This is primarily a result of the 
higher surface charge of the larger micelle formed in the 
presence of salt.  However, we can also determine how 
effectively each individual charge binds to heparin.  In the 
absence of salt, the micelles formed by C22-G1 have a total 
charge of only +44, 18 of which (Qeff) are effectively engaged 
in binding heparin (Fig. 6, top left), resulting in ȟ
ୠ୧୬ୢୣ୤୤ ୣ୤୤ൗ  of 
-1.68 kcal/mol (Table 3). On the other hand, in 150 mM NaCl, 
the larger self-assembled micelles generated by C22-G1 exploit 
32 (out of 96) positive charges to constantly bind heparin (see 
Fig. 6, top right) in a more efficient manner, as testified by the 
more favourable ȟ
ୠ୧୬ୢୣ୤୤ ୣ୤୤ൗ  value of -2.03 kcal/mol (Table 3).  
The larger more flexible micelle is therefore not only a stronger 
binder overall, but each individual charge has more effective 
binding ± for a full deconvolution of the origins of these 
enhanced binding effects ± see below. 
Table 3.  Predicted number of effective charges (Qeff), effective free energy of 
binding (ȟܩୠ୧୬ୢୣ୤୤ ), and effective-charge-normalized free energy of binding 
(ȟܩୠ୧୬ୢୣ୤୤ ୣ୤୤ ? ) for C22-G1, Protamine and G2-PAMAM binding heparin 
under high salt/no salt conditions. 
Binder Qeff ȟܩୠ୧୬ୢୣ୤୤  
(kcal/mol) 
ȟܩୠ୧୬ୢୣ୤୤ ୣ୤୤ ?  
(kcal/mol) 
150 mM NaCl 
C22-G1 32 ± 1 -65.0 ± 1.6 -2.03± 0.08 
Protamine 12 ± 1 -3.96 ± 0.41 -0.33 ± 0.04 
G2-PAMAM 13 ± 1 -16.9 ± 0.5 -1.30 ± 0.11 
0 NaCl 
C22-G1 18 ± 2 -30.2 ± 1.0 -1.68± 0.19 
Protamine 10 ± 1 -2.60 ± 0.30 -0.26± 0.04 
G2-PAMAM 15 ± 1 -22.1 ± 0.8 -1.47± 0.03 
 
 According to our calculations, protamine (modelled on a 
typical protamine sequence, as previously reported)16 is only 
marginally improved by the presence of salt (ȟ
ୠ୧୬ୢୣ୤୤ ୣ୤୤ൗ (150 
mMNaCl) - ȟ
ୠ୧୬ୢୣ୤୤ ୣ୤୤ൗ  (no salt) = -0.07 kcal/mol).  This can 
be ascribed to a balanced contribution of counteracting factors 
including the rigid tertiary structure of protamine being less 
affected by a high-salt environment, the greater screening of 
electrostatic interactions, and greater compaction of the 
polysaccharide polyelectrolyte which may increase 
intermolecular contacts (Fig. 6, middle panel).  Ionic strength 
appears to play a detrimental role in the formation of G2-
PAMAM/heparin complex (ȟܩୠ୧୬ୢୣ୤୤ ), an effect we propose is 
due to the external ions weakening the electrostatic interactions 
which form the relevant complex. We suggest that coupled to 
the limited structural reorganization of the covalently bound 
nanostructure, G2-PAMAM becomes a less effective heparin 
binder at physiological ionic strength (Fig. 6, lower panel). 
 To further support our hypothesis and investigate in detail 
the nature of the intermolecular interactions steering the 
binding process we deconvoluted the enthalpic term of the 
effective free energy of binding ȟܩୠ୧୬ୢୣ୤୤  into its different 
components. From this analysis we found that, for both G2-
PAMAM and C22-G1, and independently of the salt conditions 
applied, heparin binding is, as expected substantially driven by 
the total electrostatic term. In all cases the desolvation free 
energy penalty paid by the systems upon complexation ( ?
ୋ୆ୣ୤୤ ) 
is more than compensated by the favourable electrostatic 
interactions between heparin and its binders ( ?ୣ ୪ୣୣ୤୤ ), so that the 
total electrostatic term ( ?ୣ ୪ୣǡ୲୭୲ୣ୤୤ =  ?ୣ ୪ୣୣ୤୤  +  ?
ୋ୆ୣ୤୤ , Table S2) 
always contributes favourably to the binding.  For G2-PAMAM 
the value of  ?ୣ ୪ୣǡ୲୭୲ୣ୤୤  is -20.11 kcal/mol in the absence of salt 
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and -16.07 kcal/mol at 150 mM NaCl ± i.e. the presence of salt 
diminishes the electrostatic term.  The same total electrostatic 
component of ȟ
ୠ୧୬ୢୣ୤୤  for C22-G1 is equal to -33.49 kcal/mol 
and -67.97 kcal/mol under no/high salt conditions, respectively 
± even taking into account the larger number of C22-G1 
molecules involved when salt is present, this clearly 
demonstrated the role of electrostatics (Fig. 7).  The larger 
nanostructure induced by the presence of salt enables 
interactions with heparin which can be optimised more 
effectively to give strong electrostatic binding (Table S2). 
These stronger interactions can form more easily for the larger 
nanostructure because of the larger number of available surface 
groups.  This explains the difference between the covalent 
nanoscale array, and the salt-responsive self-assembled 
multivalent one. Not surprisingly, the overall dispersion term 
( ?ୢ ୧ୱ୮ǡ୲୭୲ୣ୤୤  =  ?୴ୢ୵ୣ୤୤  +  ?
୬୮ୣ୤୤, Table S2), although also 
favourable to binding, is lower than its electrostatic counterpart, 
and although increasing slightly for C22-G1 in the presence of 
salt, does not contribute anywhere near as much as the 
electrostatic term (Fig. 7).  Indeed, the increase in the 
dispersion term from -11.63 to -19.96 kcal/mol is much less 
significant on a per residue basis.   
Figure 7.  Deconvolution of the enthalpic term of the effective free energy of 
binding from multiscale modelling into effective total electrostatic and total 
dispersion terms ʹ demonstrating how salt induces much stronger electrostatic 
binding for C22-G1 to heparin but not for G2-PAMAM. 
 This combined experimental and theoretical study therefore 
highlights a unique and unexpected advantage of self-
assembled multivalency ± the dynamic, responsive and flexible 
stimulus-responsive nature of the SAMul array means it can 
significantly adapt on the nanoscale in different conditions,21 in 
this case, the presence of salt, optimising multivalent binding.  
We believe this may be a general principle of some importance 
in multivalent binding and is a unique way in which self-
assembled multivalent nanosystems differ from their covalent 
counterparts.  
It should be noted that multiple micellar nanostructures will, of 
course, interact with each heparin chain, leading to larger 
hierarchical aggregates.  This type of aggregation process is 
well-known to occur when protamine binds heparin.22  DLS 
supported this viewpoint for C22-G1. The aggregates formed 
by C22-G1 and heparin were much larger than the individual 
micelles or heparin chains (Table 4).  Combined with the 
evidence from SEM and Nile Red assays, we propose that the 
individual micelles remain intact within these larger aggregates. 
Table 4.  Dynamic Light Scattering (DLS) data for C22-G1 in the absence 
and presence of heparin. 
 Mol Ratio Diameter 
(nm) 
PDI 
Heparin  (0.329 mg/mL) - 8.7 0.316 
C22-G1 (1.00 mg/mL) - 9.0 0.461 
C22-G1 + Heparin 0.1:1 13.0 0.276 
C22-G1 + Heparin 0.5:1 68.9 0.155 
C22-G1 + Heparin 1:1 too large - 
Effect of Human Serum on SAMul Heparin Binding 
We next decided to probe binding in even more biologically 
relevant and challenging conditions ± human serum.  Serum is 
electrolytically rich and contains all of the proteins (except 
those involved with blood clotting), antibodies, antigens, 
hormones and other exogenous and endogenous species 
routinely present in blood.  The ability of a binder to function in 
serum would suggest a propensity to operate in blood: the 
ultimate target medium for clinical application.   
Table 5.  Heparin Binding Data from MalB &RPSHWLWLRQ$VVD\VXVLQJȝ0
0DO%DQGȝ0KHSDULQZLWKWKHKHSDULQEHLQJGHOLYHUHGLQKXPDQ
serum, 10 mM Tris-HCl. 
Binder EC50 (PM) CE50 Dose 
(mg/100IU) 
C22-G1 25.90 ± 1.60 0.96 ± 0.06 0.79 ± 0.05 
Protamine 3.51 ± 0.12 0.79 ± 0.03 0.49 ± 0.02 
G2-PAMAM 2.15 ± 0.05 0.32 ± 0.01 0.21 ± 0.01 
 
 We assayed the ability of C22-G1, protamine and G2-
PAMAM to bind heparin delivered in 100% human serum 
(Table 5).  This appears to somewhat disrupt the ability of C22-
G1 to displace MalB from its complex with heparin, increasing 
the CE50 value from 0.28 (Table 1) to 0.96 (Table 5).  
Protamine was, in relative terms, less adversely affected, with 
the CE50 value rising from 0.52 (Table 1) to only 0.79 (Table 
5).  Although salt enhanced the relative heparin-binding ability 
of C22-G1 compared to protamine, serum therefore somewhat 
diminishes it.  In contrast to protamine and C22-G1, G2-
PAMAM actually decreased its CE50 from 0.38 to 0.32, 
indicating it is even better able to displace MalB in human 
serum.  This may appear to suggest that PAMAM dendrimers 
are best for this application, but as demonstrated in the 
literature, such dendrimers are not ideal for in vivo use.13,23 
 There is therefore a clear difference between the covalent 
and self-assembled nanostructures ± unlike in salt, in serum the 
self-assembled C22-G1 system loses some of its apparent 
binding capacity relative to covalent systems.  We considered 
this may be because the SAMul nanostructures disassemble in 
human serum to yield individual molecular building blocks, 
each of which would only have four poorly organised positive 
charges.  Disassembly of micelles in serum is known,24 for 
example, the hydrophobic units can bind to albumin and/or 
globulin proteins, and interact with charged surface patches on 
serum proteins.  We probed the effect of albumin on complexes 
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formed between C22-G1 and heparin using DLS (Table 6) ± on 
exposure to albumin, the aggregates gradually (over time) 
became smaller, which may be explained by some 
destabilisation of the C22-G1 assemblies, lowering their 
affinity for heparin somewhat ± but the binding is clearly not 
completely switched off, or the aggregates completely 
disassembled. 
 Importantly, non-self-assembling analogues were 
completely unable to displace MalB in serum, and we therefore 
reasoned that C22-G1 does not completely disassemble in 
human serum, and that its self-assembly is only partially 
compromised.  In order to probe the effect of serum in more 
detail, we monitored the ability of C22-G1 to displace MalB in 
the presence of increasing amounts of serum.  We noted that on 
increasing serum levels from 1% to 10% there was a sequential 
increase in the disruption of binding.  Human serum (10%) 
induced a similar disruption in binding to 100% (see supp info).   
Table 6.  Dynamic Light Scattering (DLS) data for C22-G1 and  heparin in 
the absence and presence of albumin (1 mg/mL),  
 Mol Ratio Diameter 
(nm) 
PDI 
C22-G1 + Heparin 0.5:1 68.9 0.155 
C22-G1 + Heparin + 
Albumin 
0.5:1 62.6 0.272 
C22-G1 + Heparin + 
Albumin (after 30 min) 
0.5:1 55.9 0.220 
 
 Although the binding of C22-G1 to heparin in human serum 
is disrupted more than covalent analogues, it was still effective 
(CE50 <1.0), and given the other potential advantages of our 
SAMul approach,4a we were nonetheless encouraged to press 
on with further studies. 
Degradation and Disassembly of C22-G1 at Biological pH 
A key advantage of a SAMul approach to heparin binding is 
that the resulting nanostructures are potentially degradable.  
This can occur through (i) simple nanoparticle disassembly, or 
(ii) triggered bond cleavage.  The design of C22-G1 
incorporates an ester linkage between the hydrophobic tail and 
the hydrophilic heparin-binding unit.  Esters are well-known to 
degrade under biological conditions of pH and/or in the 
presence of enzymes.  Both our group,18d,25 and that of 
Fréchet,26 have probed the disassembly of related dendrons and 
reported this as a means of achieving temporary multivalency 
in biological systems, and limiting biopersistence/toxicity.  In 
this case, cleavage of the ester bond would lead to loss of the 
amphiphilic character of C22-G1 and in addition to dendron 
breakdown, should trigger complete disassembly of the SAMul 
nanostructure, switching off its biological activity.   
 We used mass spectrometric (MS) analysis in the presence 
of an internal standard (Gly-Ala) to look at the loss of 
molecular ion.  At time zero, the molecular ions associated with 
C22-G1 (m/z = 433 [M]2+ and 289 [M]3+) could be seen ± there 
was also some evidence for ester hydrolysis (alcohol, m/z = 408 
[1+]; carboxylic acid, m/z = 239 [M]2+) (see SI for full data).  
After 24 hours, the molecular ions for intact C22-G1 had 
completely disappeared, and the peaks for ester hydrolysis were 
dominant, along with a peak corresponding to decarboxylation 
of the carboxylic acid hydrolysis product (m/z = 217, [M]2+).  
This demonstrates that degradation of this compound is 
relatively facile under biologically relevant conditions of pH. 
 We then wanted to demonstrate that degradation would 
cause nanostructure disassembly.  We left C22-G2 in PBS 
buffer in the presence of Nile Red,17 in order to probe whether 
degradation over a 24 hour timescale led to disassembly and 
release of encapsulated Nile Red.  At time zero, the 
fluorescence intensity was high, as intact C22-G1 self-
assembled and encapsulated Nile Red (Fig. 8).  After 24 hours, 
the fluorescence had dropped back close to the level observed 
for Nile Red in the absence of C22-G1.  As such, we conclude 
that degradation of C22-G1 leads to nanoscale disassembly. 
Fig. 8.  Fluorescence intensity of Nile Red in PBS Buffer over 24 hours in the 
presence of C22-G1 and C22-G1 with heparin. 
 We repeated this Nile Red release study in the presence of 
heparin (Fig. 8).  It should be noted that in this experiment, the 
C22-G1-heparin complexes slowly sedimented from solution 
owing to their large nanoscale dimensions (see DLS data 
presented above) ± as such, the vial was gently inverted prior to 
each spectroscopic measurement to ensure mixing.  After 24 
hours, there was still a significant fluorescence intensity 
associated with Nile Red.  This suggests that in the presence of 
heparin, C22-G1 is much more resistant to degradation, and the 
nanoscale micelles retain their stability.   
 This agrees with our previous studies of related DNA-
binding systems which showed that when bound to DNA, 
intramolecular amine catalysis of ester degradation was 
inhibited and the multivalent system retained both stability and 
DNA binding ability.18d  As such, the degradation profile of 
C22-G1 is of potential therapeutic use for heparin rescue.  
Excess C22-G1 will degrade and disassemble over a relatively 
rapid timescale, minimising adverse effects, but C22-G1 bound 
to heparin, is more stable, hopefully allowing excretion of the 
complex to take place prior to degradation and disassembly. 
Clotting Assays Using SAMul in Human Plasma 
Ultimately, the most important functional test of C22-G1 is 
whether it can reverse the effect of heparin in a biomedically-
relevant assay.  This was probed by determining the ability of 
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C22-G1 to reverse heparin-induced anti-coagulation.  Blood 
clotting (thrombogenesis) occurs in two stages:27 (i) platelets 
form a cross-linked plug at the site of injury, (ii) a complex 
cascade of clotting factors convert soluble plasma glycoprotein 
fibrinogen to insoluble fibrin. This blood coagulation cascade 
can EHVLPSOLILHGLQWRWZRSDWKZD\VLWKHµLQWULQVLFSDWKZD\¶  
originating from surface contact trauma LL WKH µH[WULQVLF¶
pathway originating from tissue damage. The intrinsic pathway 
plays a minor role in overall clotting and can be monitored by 
measuring an activated partial thromboplastin time (aPTT 
assay).  In the extrinsic pathway, there are relatively few steps 
from initial trauma to the production of Factor Xa which is 
required in large amounts, and this is therefore the dominant 
route in the overall coagulation cascade ± it is monitored by 
measuring prothrombin clotting time (PT assay). 
Table 7.  Heparin Binding Data from aPTT and PT clotting assays in human 
plasma. 
 Clotting Time (s) 
 aPTT Assaya PT assayb 
Plasma Only 35.7 ± 0.7 12.8 ± 0.8 
+ Heparin None None 
+ C22 G1 81.8 ± 4.6 13.1 ± 0.4 
a: aPTT assay performed with 2.5 units of heparin dose and C22-G1 
applied at 0.79 mg/100IU.  b: PT assay performed with 5 units of 
heparin dosed and C22-G1 applied at 0.79 mg/100 IU. 
 
 We monitored the ability of C22-G1 to reverse the effect of 
heparin using aPTT (intrinsic) and PT (extrinsic) assays (Table 
7). In the absence of heparin, the plasma clotted in 35.7 s (aPTT 
assay) and 12.8 s (PT assay).  On the addition of heparin, 
clotting no longer occurred, as heparin exerted its anti-
coagulant effect.  We then added C22-G1 at an appropriate 
dose.  In both assays, C22-G1 induced clotting ± demonstrating 
it is capable of functional heparin reversal.  In the aPTT assay, 
the clotting time was somewhat elevated at 81.8 s, but in the PT 
assay, the clotting time was very similar to native plasma, at 
13.1 s.  These experiments demonstrate that even though our 
binding studies in 100% human serum indicated some decrease 
in heparin affinity, these self-assembled multivalent systems are 
active in plasma.  Clearly, if we can further stabilise the SAMul 
nanostructures, we may be able to further enhance heparin 
binding and clotting times, particularly in the aPTT assay.  
Nonetheless, it is clear that with appropriate optimisation of 
structure, dosage and delivery mode, SAMul systems such as 
C22-G1 are potentially very promising therapeutic agents for 
heparin rescue. 
Conclusions 
In conclusion, C22-G1 is a heparin binder in which self-
assembly into nanoscale structures plays a key role in 
multiplying up the ligand array for multivalent heparin binding.  
The dynamic and responsive nature of self-assembly means that 
the addition of salt changes the dimensions of the self-
assembled nanostructure and increases heparin binding affinity 
relative to fixed covalent nanostructures ± a unique feature of 
the SAMul approach.  The presence of serum adversely affects 
heparin affinity relative to covalent nanostructures, which we 
assign to partial destabilisation of the self-assemblies under 
these conditions.  Degradation and disassembly take place as a 
result of ester hydrolysis, leading to loss of SAMul binding 
over a 24 hour timescale, but once bound to heparin, the 
nanostructure is more stable ± a clinically useful profile.  
Clotting assays in human plasma demonstrate that C22-G1 acts 
as a functional heparin reversal agent, and we therefore suggest 
that this general approach has clinical potential.  Further 
optimisation of these SAMul systems and extended structure-
activity relationship studies are currently underway in order to 
(i) better understand heparin binding in fundamental terms, and 
(ii) further stabilise the self-assemblies prior to clinical 
application in highly competitive human blood. 
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Graphical Abstract: 
Dynamic and responsive self-assembled multivalent 
ligand arrays yield functional heparin reversal in highly 
competitive media such as human plasma. 
 
 
 
 
